AIDX.TO Healwell AI Inc. (TSX) pre-market 17 Feb 2026: C$0.67, model flags downside

AIDX.TO stock opens pre-market on 17 Feb 2026 at C$0.67, down 1.47% from the prior close. Healwell AI Inc. (AIDX.TO) trades on the TSX with a market cap of C$186.53M and a 50-day average price of C$0.85. Investors in AI healthcare names should weigh weak profitability metrics against product partnerships and sector momentum. This note frames the near-term technical picture, fundamentals, Meyka AI forecast, and realistic price targets for AIDX.TO stock.

AIDX.TO stock: quick snapshot and intraday drivers

Healwell AI Inc. (AIDX.TO) is trading pre-market at C$0.67 with intraday range C$0.65–C$0.70 and volume of 778,693 shares. The stock is below its 50-day average of C$0.85 and 200-day average of C$1.22, signaling shorter-term weakness.

Primary intraday drivers include recent sector weakness in healthcare tech and the company’s negative EPS of -0.23 and trailing PE of -2.91, which keep sentiment cautious for AIDX.TO stock.

Fundamentals and valuation: where AIDX.TO stands

Healwell reports revenue per share TTM of C$0.42 and book value per share of C$0.52. Key ratios show price-to-sales 1.86, price-to-book 1.32, and enterprise value to sales 2.59. These multiples sit below many growth tech names but above defensive healthcare peers, reflecting mixed growth expectations.

Balance sheet and cash flow metrics show current ratio 0.85 and free cash flow per share TTM of -C$0.11, highlighting liquidity pressure. Debt-to-equity is 0.74, modest but notable given negative operating cash flow. These fundamentals explain why valuations for AIDX.TO stock trade with a discount to higher-quality sector peers.

Technicals and momentum: short-term map for AIDX.TO stock

Technical indicators show an RSI of 36.81 and ADX 43.03, indicating a strong downtrend with limited immediate oversold relief. MACD is slightly negative with histogram 0.01, suggesting weak momentum.

Price action sits under the 50-day and 200-day averages, and OBV is negative at -6,553,372, which confirms distribution. For traders, a decisive move above C$0.87 (50-day) would be the first sign of momentum shift for AIDX.TO stock.

Meyka AI grade and forecast for AIDX.TO stock

Meyka AI rates AIDX.TO with a score out of 100: 53.98 (C+) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Grades are informational and not financial advice.

Meyka AI’s forecast model projects monthly C$0.54, quarterly C$0.64, and yearly C$0.47. Versus the current C$0.67, that implies a monthly downside of -19.40%, a quarterly downside of -4.48%, and a 12-month downside of -29.32%. Forecasts are model-based projections and not guarantees.

Valuation scenarios and price targets for AIDX.TO stock

We set three scenario targets: conservative short-term target C$0.50 (stress case), base-case 12-month target C$0.47 (model median), and optimistic target C$1.20 (reversion to 200-day average if product traction accelerates). The base-case target aligns with Meyka AI’s yearly forecast.

Implied moves from the current price C$0.67 are: conservative -25.37%, base-case -29.32%, and optimistic +79.10%. Use scenario sizing and stop-loss rules given AIDX.TO stock’s volatility and thin current ratio.

Risks, catalysts and sector context for AIDX.TO stock

Key risks: continued negative operating cash flow, EPS trend pressure, and sector rotation away from small-cap AI healthcare names. The company’s next earnings announcement is scheduled for 26 Mar 2026, a possible catalyst for volatility.

Potential catalysts: commercialization updates with healthcare partners, better-than-expected margin improvement, or sector re-rating in AI healthcare. Compared to the broader Canadian healthcare sector averages, Healwell shows weaker liquidity and profitability metrics, so positive execution is required to shift the outlook for AIDX.TO stock.

Final Thoughts

Key takeaways for AIDX.TO stock: Healwell AI trades at C$0.67 pre-market on 17 Feb 2026 with elevated volatility and distribution on the tape. Fundamentals show revenue per share C$0.42, negative EPS -0.23, weak cash flow, and a current ratio 0.85, which together justify caution. Meyka AI rates AIDX.TO 53.98 (C+) — HOLD and its forecast model projects a 12-month price near C$0.47 (implied -29.32% versus today). Scenario targets range from C$0.50 (stress) to C$1.20 (bull case tied to 200-day reversion). Investors focused on AI stocks should treat AIDX.TO as a higher-risk, event-driven name and size positions accordingly. For further company details, see the Healwell website and our platform notes on the Meyka AIDX.TO stock page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.